Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist

Peptides

Volumn 29, Issue 1, 2008, Pages 93-103

  Vergura, Raffaella ^a   Balboni, Gianfranco ^b,c   Spagnolo, Barbara ^a   Gavioli, Elaine ^a   Lambert, David G ^d   McDonald, John ^d   Trapella, Claudio ^e   Lazarus, Lawrence H ^f   Regoli, Domenico ^a   Guerrini, Remo ^b   Salvadori, Severo ^b   Caló, Girolamo ^a  

^a National Institute of Neuroscience   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UFPeptides srl   (Italy)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Bioassay; DOP receptor; Elevated plus maze test; Forced swimming test; Light dark aversion; Receptor binding; UFP 512

Indexed keywords

DELTA OPIATE RECEPTOR AGONIST; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); NALTRINDOLE; OPIATE RECEPTOR; UFP 512; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL MEMBRANE; CHO CELL; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTROSTIMULATION; FORCED SWIMMING TEST; IMMOBILIZATION; LIGHT DARK CYCLE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; TRANQUILIZING ACTIVITY; VAS DEFERENS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZIMIDAZOLES; BINDING SITES; CHO CELLS; CRICETINAE; CRICETULUS; DARKNESS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; LIGANDS; LIGHT; MALE; MAZE LEARNING; MICE; MOLECULAR CONFORMATION; MOTOR ACTIVITY; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RETENTION (PSYCHOLOGY); STRUCTURE-ACTIVITY RELATIONSHIP; SWIMMING;

RATTUS; RODENTIA;

EID: 37449031281     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.10.012     Document Type: Article

References (43)

1. Aguila B, Coulbault L, Boulouard M, Léveillé F, Davis A, Tòth G, et al. In vitro and in vivo pharmacological profile of UFP-512, a novel selective δ-opioid receptor agonist: function and trafficking studies correlate with the lack of tolerance. Br J Pharmacol 2007, in press.
2. Baamonde A., Dauge V., Ruiz-Gayo M., Fulga I.G., Turcaud S., Fournie-Zaluski M.C., et al. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur J Pharmacol 216 (1992) 157-166
3. Balboni G., Guerrini R., Salvadori S., Bianchi C., Rizzi D., Bryant S.D., et al. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem 45 (2002) 713-720
4. Balboni G., Salvadori S., Guerrini R., Negri L., Giannini E., Jinsmaa Y., et al. Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem 45 (2002) 5556-5563
5. Barros H.M., and Ferigolo M. Ethopharmacology of imipramine in the forced-swimming test: gender differences. Neurosci Biobehav Rev 23 (1998) 279-286
6. Berger H., Calo G., Albrecht E., Guerrini R., and Bienert M. [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain. J Pharmacol Exp Ther 294 (2000) 428-433
7. Bigoni R., Giuliani S., Calo G., Rizzi A., Guerrini R., Salvadori S., et al. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol 359 (1999) 160-167
8. Brawman-Mintzer O., and Yonkers K.A. New trends in the treatment of anxiety disorders. CNS Spectr 9 (2004) 19-27
9. Broom D.C., Jutkiewicz E.M., Folk J.E., Traynor J.R., Rice K.C., and Woods J.H. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 26 (2002) 744-755
10. Cahill C.M., McClellan K.A., Morinville A., Hoffert C., Hubatsch D., O'Donnell D., et al. Immunohistochemical distribution of delta opioid receptors in the rat central nervous system: evidence for somatodendritic labeling and antigen-specific cellular compartmentalization. J Comp Neurol 440 (2001) 65-84
11. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
12. Choleris E., Thomas A.W., Kavaliers M., and Prato F.S. A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field. Neurosci Biobehav Rev 25 (2001) 235-260
13. Cox B.M., Chavkin C., Christie M.J., Civelli O., Evans C., Hamon M.D., et al. The IUPHAR compendium of receptor characterization and classification (2000), IUPHAR Media Ltd., London pp. 321-33
14. Detke M.J., Rickels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121 (1995) 66-72
15. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H.W., Simonin F., et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25 (2000) 195-200
16. Gavioli E.C., Marzola G., Guerrini R., Bertorelli R., Zucchini S., De Lima T.C., et al. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci 17 (2003) 1987-1990
17. Gavioli E.C., Vaughan C.W., Marzola G., Guerrini R., Mitchell V.A., Zucchini S., et al. Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 547-553
18. George S.R., Zastawny R.L., Briones-Urbina R., Cheng R., Nguyen T., Heiber M., et al. Distinct distributions of mu, delta and kappa opioid receptor mRNA in rat brain. Biochem Biophys Res Commun 205 (1994) 1438-1444
19. Gouarderes C., Jhamandas K., Cridland R., Cros J., Quirion R., and Zajac J.M. Opioid and substance P receptor adaptations in the rat spinal cord following sub-chronic intrathecal treatment with morphine and naloxone. Neuroscience 54 (1993) 799-807
20. Jutkiewicz E.M. The antidepressant -like effects of delta-opioid receptor agonists. Mol Interv 6 (2006) 162-169
21. Kang W., Wilson S.P., and Wilson M.A. Overexpression of proenkephalin in the amygdala potentiates the anxiolytic effects of benzodiazepines. Neuropsychopharmacology 22 (2000) 77-88
22. Kita A., Imano K., Seto Y., Yakuo I., Deguchi T., and Nakamura H. Antinociceptive and antidepressant-like profiles of BL-2401, a novel enkephalinase inhibitor, in mice and rats. Jpn J Pharmacol 75 (1997) 337-346
23. Kitayama M., Barnes T.A., Carra G., McDonald J., Calo G., Guerrini R., et al. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2. Naunyn Schmiedebergs Arch Pharmacol 368 (2003) 528-537
24. Konig M., Zimmer A.M., Steiner H., Holmes P.V., Crawley J.N., Brownstein M.J., et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383 (1996) 535-538
25. Koster A., Montkowski A., Schulz S., Stube E.M., Knaudt K., Jenck F., et al. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci USA 96 (1999) 10444-10449
26. Laursen S.E., and Belknap J.K. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 16 (1986) 355-357
27. Mansour A., Fox C.A., Burke S., Meng F., Thompson R.C., Akil H., et al. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 350 (1994) 412-438
28. Mansour A., Thompson R.C., Akil H., and Watson S.J. Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J Chem Neuroanat 6 (1993) 351-362
29. Mokhtari M., Tafani J.A., and Zajac J.M. Binding in vivo of selective mu and delta opioid agonists: localization by autoradiography. Neuropeptides 25 (1993) 183-191
30. Neubig R.R., Spedding M., Kenakin T., and Christopoulos A. International Union of Pharmacology Committee on receptor nomenclature and drug classification, XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55 (2003) 597-606
31. Pacher P., and Ungvari Z. Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses 57 (2001) 469-471
32. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
33. Ragnauth A., Schuller A., Morgan M., Chan J., Ogawa S., Pintar J., et al. Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci USA 98 (2001) 1958-1963
34. Reneric J.P., Bouvard M., and Stinus L. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 136 (2002) 521-532
35. Rizzi A., Bigoni R., Marzola G., Guerrini R., Salvadori S., Regoli D., et al. Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn Schmiedebergs Arch Pharmacol 363 (2001) 161-165
36. Rizzi A., Rizzi D., Marzola G., Regoli D., Larsen B.D., Petersen J.S., et al. Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice. Br J Pharmacol 137 (2002) 369-374
37. Saitoh A., Kimura Y., Suzuki T., Kawai K., Nagase H., and Kamei J. Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 95 (2004) 374-380
38. Salvadori S., Attila M., Balboni G., Bianchi C., Bryant S.D., Crescenzi O., et al. Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med 1 (1995) 678-689
39. Tejedor-Real P., Mico J.A., Maldonado R., Roques B.P., and Gibert-Rahola J. Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biol Psychiatry 34 (1993) 100-107
40. Tejedor-Real P., Mico J.A., Maldonado R., Roques B.P., and Gibert-Rahola J. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 52 (1995) 145-152
41. Tejedor-Real P., Mico J.A., Smadja C., Maldonado R., Roques B.P., and Gilbert-Rahola J. Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol 354 (1998) 1-7
42. Torregrossa M.M., Jutkiewicz E.M., Mosberg H.I., Balboni G., Watson S.J., and Woods J.H. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res 1069 (2006) 172-181
43. Vergura R., Valenti E., Hebbes C.P., Gavioli E.C., Spagnolo B., McDonald J., et al. Dmt-Tic-NH-CH(2)-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies. Peptides 27 (2006) 3322-3330